UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 231

Sortiert nach

Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges

Drug safety, 2014-11, Vol.37 (Suppl 1), p.9-17

Senior, John R.

2014

Link zum Volltext

Verfügbarkeit prüfen

Medium Chain Triglycerides

1, 1968

Link zum Volltext

Verfügbarkeit prüfen

Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions

Toxicologic pathology, 2005-01, Vol.33 (1), p.155-164

2005

Link zum Volltext

Verfügbarkeit prüfen

Drug Hepatotoxicity from a Regulatory Perspective

Clinics in liver disease, 2007-08, Vol.11 (3), p.507-524

Senior, John R., MD

2007

Link zum Volltext

Verfügbarkeit prüfen

Drug-Related Hepatotoxicity

The New England journal of medicine, 2006-02, Vol.354 (7), p.731-739

2006

Link zum Volltext

Verfügbarkeit prüfen

Can rechallenge be done safely after mild or moderate drug‐induced liver injury?

Hepatology (Baltimore, Md.), 2016-03, Vol.63 (3), p.691-693

Senior, John R.

2016

Link zum Volltext

Verfügbarkeit prüfen

New biomarkers for drug-induced liver injury: are they really better? what do they diagnose?

Liver international, 2014-03, Vol.34 (3), p.325-327

Senior, John R.

2014

Link zum Volltext

Verfügbarkeit prüfen

Why the threshold criteria should not be modified for detection of possibly serious drug-induced hepatotoxicity in special groups of trial subjects

Pharmacoepidemiology and drug safety, 2013-06, Vol.22 (6), p.579-582

Senior, John R.

2013

Link zum Volltext

Verfügbarkeit prüfen

What is idiosyncratic hepatotoxicity? What is it not?

Hepatology (Baltimore, Md.), 2008-06, Vol.47 (6), p.1813-1815

Senior, John R.

2008

Link zum Volltext

Verfügbarkeit prüfen

Using controlled clinical trials to learn more about acute drug‐induced liver injury

Hepatology (Baltimore, Md.), 2008-11, Vol.48 (5), p.1680-1689

2008

Link zum Volltext

Verfügbarkeit prüfen

Unintended Hepatic Adverse Events Associated with Cancer Chemotherapy

Toxicologic pathology, 2010-01, Vol.38 (1), p.142-147

Senior, John R.

2010

Link zum Volltext

Verfügbarkeit prüfen

Some Recollections of the American Association for the Study of Liver Diseases Transformative Decade 1970‐1979

Hepatology communications, 2017-02, Vol.1 (1), p.71-75

Senior, John R.

2017

Link zum Volltext

Verfügbarkeit prüfen

The Clinical Liver Safety Assessment Best Practices Workshop: Rationale, Goals, Accomplishments and the Future

Drug safety, 2014-11, Vol.37 (Suppl 1), p.1-7

2014

Link zum Volltext

Verfügbarkeit prüfen

How can 'Hy's law' help the clinician?

Pharmacoepidemiology and drug safety, 2006-04, Vol.15 (4), p.235-239

Senior, John R.

2006

Link zum Volltext

Verfügbarkeit prüfen

The Australia antigen and role of the late Philadelphia general hospital in reducing post‐transfusion hepatitis and sequelae

Hepatology (Baltimore, Md.), 2011-09, Vol.54 (3), p.753-756

2011

Link zum Volltext

Verfügbarkeit prüfen

CURRENT CONCEPTS: Drug-Related Hepatotoxicity

The New England journal of medicine, 2006-02, Vol.354 (7), p.731

2006

Link zum Volltext

Verfügbarkeit prüfen

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30‐month pilot study

Hepatology (Baltimore, Md.), 1991-11, Vol.14 (5), p.838-847

1991

Link zum Volltext

Verfügbarkeit prüfen

Healthy ranges for alanine aminotransferase levels

Annals of internal medicine, 2003-01, Vol.138 (2), p.156

2003

Link zum Volltext

Verfügbarkeit prüfen

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

Annals of internal medicine, 1995-08, Vol.123 (4), p.241

1995

Link zum Volltext

Verfügbarkeit prüfen

Drug‐Induced Liver Injury: Clinical and Diagnostic Aspects

Antitargets and Drug Safety, 2015, p.81-106

2015

Link zum Volltext

Verfügbarkeit prüfen

Working group session report: chronic renal and gastrointestinal disease

The Journal of nutrition, 1999, Vol.129 (1S), p.313S-314S

1999

Link zum Volltext

Verfügbarkeit prüfen

REPLACEMENT OF DIETARY FAT BY MEDIUM CHAIN TRIGLYCERIDES IN CIRRHOTIC PATIENTS

Medium Chain Triglycerides, 2016, p.165-172

617.71, 2016

Link zum Volltext

Verfügbarkeit prüfen

Summary Panel on Role of Medium Chain Triglycerides in Human Disease States and Possible Future Applications

Medium Chain Triglycerides, 2016, p.247-262

617.71, 2016

Link zum Volltext

Verfügbarkeit prüfen

MECHANISMS OF ABSORPTION OF LONG AND MEDIUM CHAIN TRIGLYCERIDES

Medium Chain Triglycerides, 2016, p.21-34

617.71, 2016

Link zum Volltext

Verfügbarkeit prüfen

INTRALUMINAL FACTORS IN THE ABSORPTION OF GLYCERIDES

Medium Chain Triglycerides, 2016, p.9-20

617.71, 2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 231

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(163)
Mit Volltextzugriff
(202)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges

Medium Chain Triglycerides

Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions

Drug Hepatotoxicity from a Regulatory Perspective

Drug-Related Hepatotoxicity

Can rechallenge be done safely after mild or moderate drug‐induced liver injury?

New biomarkers for drug-induced liver injury: are they really better? what do they diagnose?

Why the threshold criteria should not be modified for detection of possibly serious drug-induced hepatotoxicity in special groups of trial subjects

What is idiosyncratic hepatotoxicity? What is it not?

Using controlled clinical trials to learn more about acute drug‐induced liver injury

Unintended Hepatic Adverse Events Associated with Cancer Chemotherapy

Some Recollections of the American Association for the Study of Liver Diseases Transformative Decade 1970‐1979

The Clinical Liver Safety Assessment Best Practices Workshop: Rationale, Goals, Accomplishments and the Future

How can 'Hy's law' help the clinician?

The Australia antigen and role of the late Philadelphia general hospital in reducing post‐transfusion hepatitis and sequelae

CURRENT CONCEPTS: Drug-Related Hepatotoxicity

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30‐month pilot study

Healthy ranges for alanine aminotransferase levels

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

Drug‐Induced Liver Injury: Clinical and Diagnostic Aspects

Working group session report: chronic renal and gastrointestinal disease

REPLACEMENT OF DIETARY FAT BY MEDIUM CHAIN TRIGLYCERIDES IN CIRRHOTIC PATIENTS

Summary Panel on Role of Medium Chain Triglycerides in Human Disease States and Possible Future Applications

MECHANISMS OF ABSORPTION OF LONG AND MEDIUM CHAIN TRIGLYCERIDES

INTRALUMINAL FACTORS IN THE ABSORPTION OF GLYCERIDES

Suchergebnisse filtern